Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study

Brain metastases (BMs) are associated with poor prognosis in epidermal growth factor receptor mutation‐positive (EGFRm) non‐small cell lung cancer (NSCLC). Osimertinib is a third‐generation, irreversible, EGFR‐tyrosine kinase inhibitor that potently and selectively inhibits EGFR‐sensitizing and T790...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekman, Simon, Cselényi, Zsolt, Varrone, Andrea, Jucaite, Aurelija, Martin, Heather, Schou, Magnus, Johnström, Peter, Laus, Gianluca, Lewensohn, Rolf, Brown, Andrew P., van der Aart, Jasper, Vishwanathan, Karthick, Farde, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264937/
https://www.ncbi.nlm.nih.gov/pubmed/36808835
http://dx.doi.org/10.1111/cts.13500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264937/
https://www.ncbi.nlm.nih.gov/pubmed/36808835
http://dx.doi.org/10.1111/cts.13500

Ejemplares similares